Organic Active Ingredients TRIZ Cases

Combining nifedipine with a PGF2α receptor antagonist delays labor onset through synergistic uterine relaxation.

Compounds targeting BRG1 and BRM proteins treat disorders where prior therapies failed to modulate BAF complex activity effectively.

A block copolymer carrier uses a cationic segment to bind siRNA and a hydrophilic chain to shield the complex.

Allele-specific siRNAs selectively suppress mutant ACVR1 expression, reducing heterotopic ossification in Fibrodysplasia Ossificans Progressiva.

Amorphous perindopril sodium salt formulation uses sodium hydrogen carbonate to prevent ester hydrolysis and maintain pharmaceutical stability.

Antisense oligonucleotides cleave MAPT pre-mRNA via nuclease recruitment, reducing Tau expression to treat neurodegenerative disorders.

Segmented lacosamide dosage form reduces peak-trough fluctuations and adverse reactions by maintaining stable therapeutic blood levels for 24 hours.

A dual drug portion system segments lidocaine salt and base into separate housings within a single elastic tube, enabling precise control over release kinetics.

Dual-acting fused gamma-carbolines bypass ketamine side effects by activating mTOR pathways for immediate depression relief.

Roseoflavin and trametinib target the riboflavin pathway to overcome ineffective conventional treatments for pancreatic cancer.

Formula I alkylated piperazine compounds inhibit Bruton's tyrosine kinase to treat autoimmune diseases and cancers.

Bivalent compounds conjugate a CBP P300 ligand to a degradation tag, inducing targeted protein breakdown via ubiquitin ligase recruitment.

Combining oral paracetamol with topical diclofenac emulgel targets pain and inflammation through complementary mechanisms.

Bacterial metabolite-derived ALPK1 agonists resolve treatment reliability gaps by inducing targeted immune activation and synergistic anti-tumor effects.

Amino acid combination with hyaluronic acid modulates gene expression to accelerate wound healing in oral mucositis.

CD73 inhibitors block enzymatic activity to reduce adenosine, reversing immunosuppression and sensitizing tumors to therapy.

Local quality and asymmetry design enable selective inhibition of FABP5 and FABP7, increasing extracellular anandamide levels for targeted pain relief.

Form-P crystallization of Erlotinib hydrochloride using methylene chloride and dry HCl gas eliminates hazardous solvents while ensuring thermodynamic stability.

2,4-disubstituted pyrimidine compounds inhibit protein kinases through irreversible covalent bonding to cysteine residues in the kinase domain.

PAC-1 analogues chelate labile zinc to activate procaspase-3, overcoming resistance in cancers with elevated enzyme levels.

Processing bioabsorbable polymer-drug solutions through solvent evaporation maintains drug integrity while enabling high loading capacity.

Porphyrin-phospholipid nanovesicles resolve stability versus control contradictions by using NIR-triggered phase transitions for precise drug delivery.

Formula I compounds inhibit BET family bromodomains, addressing the need for effective inhibitors across multiple disease indications.

Combines Andrographis, Astragalus, Eleuthero, Isatis, Lomatium, Pelargonium, Sambucus, Scute, and Zinc to inhibit viral reproduction.

Formula I compounds inhibit eIF4A activity, resolving the trade-off between specific cancer pathway targeting and off-target translation effects.

Abasic antisense oligomers modulate splicing precision in intron 1, resolving insufficient modulation of conventional sequences.

Engineered HNF4A mRNA variants achieve higher expression levels and longer-lasting activity to treat liver diseases like fibrosis and cirrhosis.

Adding methionine and antioxidants prevents light-induced oxidation, maintaining immunoconjugate stability without complex formulation changes.

GalNAc conjugates direct siRNA to hepatocytes via receptor binding, resolving systemic delivery specificity issues.

Dry granulation eliminates sulfurous odor in high-dose N-acetylcysteine tablets, reducing size and excipient load.

Short surfactant peptides self-assemble into nanospheric structures for therapeutic delivery.

Segmented enteric-coated microgranules suspended in triglyceride esters prevent acid degradation and extend shelf life beyond one month.

N-methylalaninyl maytansinol linkers resist endosomal oxidation while enabling protease cleavage for targeted drug release.

Glucose oxidase enzyme combined with dietary fibers and polyols manages blood sugar levels while providing a safe, sugar-like taste.

Antisense oligomers target C6 mRNA to suppress protein expression, blocking membrane attack complex formation that inhibits nerve regeneration.

Structural modifications to the maytansinoid core enhance ADC stability and potency while reducing non-specific toxicity.

Bisulfite agents convert insoluble beta-lapachone into soluble hydroxy sulfonate derivatives, resolving low solubility and enhancing bioavailability.

Isthmin-1 protein activates PI3K/AKT signaling to increase adipose glucose uptake while suppressing hepatic lipid synthesis.

Low-temperature reaction with organic solvents produces high-purity ferric citrate hydrate, reducing secondary impurities that cause peptic ulcers.

Segmenting AMPA receptors via TARP γ8 binding reduces sedation and ataxia side effects while maintaining anti-convulsant activity.

Targeting ribose-5-phosphate isomerase A via RNAi overcomes chemoresistance and inhibits migration in solid tumors.

Formula I dimers inhibit NFkB nuclear translocation, resolving toxicity trade-offs while maintaining therapeutic efficacy.

Combined sEH inhibition and ER stress reduction modulates epoxy fatty acid levels to treat neuropathic pain.

Ovatodiolide targets E6 and E7 proteins to induce selective apoptosis in HPV-positive cancer cells while sparing healthy primary tissues.

Novel pyridine derivatives combine phosphodiesterase 4 inhibition with muscarinic M3 antagonism to deliver bronchodilation and anti-inflammatory effects.

Sulfoximine glycosidase inhibitors resolve non-specific enzyme inhibition by targeting O-GlcNAcase, improving brain penetration for Alzheimer's treatment.

Combining HDAC6 and PD-L1 inhibitors reduces adverse effects from pan-HDAC inhibition while arresting cancer cell growth.